SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 9, 2004
-----------------
SANGUI BIOTECH INTERNATIONAL, INC.
(Exact name of Registrant as specified in its charter)
Colorado
(State or other jurisdiction of Incorporation or organization)
000-21271 84-1330732
------------------------ -------------------------------
(Commission File Number) (IRS. Employer Identification No.)
Alfred-Herrhausen-Str. 44, 58455 Witten, Germany
-------------------------------------------------
(Address of principal executive offices) (Zip Code)
011-49-2302-915-204
--------------------------------------------------
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
1
Item 4.01. Changes In Registrant's Certifying Accountant.
(a) Previous Independent Accountants.
(i) On September 9, 2004, Corbin & Company, LLP was dismissed as the
Company's independent accountants.
(ii) None of the reports of Corbin & Company, LLP (formerly Corbin &
Wertz, LLP as it relates to the fiscal year ended June 30, 2002) on the
financial statements for the fiscal years ended June 30, 2002 and 2003,
contained an adverse opinion or disclaimer of opinion or were qualified or
modified as to uncertainty, audit scope or accounting principles.
(iii) The decision to change accountants was recommended and approved
by the Company's board of directors.
(iv) During the years ended June 30, 2002 and 2003 and through
September 9, 2004, there were no disagreements with Corbin & Company, LLP
on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure which, if not resolved to Corbin
& Company, LLP's satisfaction, would have caused them to make reference to
the subject matter of such disagreements in connection with their report on
the Company's financial statements for such years.
(v) During the fiscal years ended June 30, 2002 and 2003 and through
September 9, 2004, there have been no reportable events (as defined in
Regulation S-K Item 304(a)(l)(v)).
(b) Newly Engaged Independent Accountants.
On September 9, 2004, the Company engaged HJ & Associates, LLC, as its
new independent accountant. Through September 9, 2004, neither the Company
nor anyone on its behalf consulted HJ & Associates, LLC, regarding (i) the
application of accounting principles to any transaction, either completed
or proposed, or (ii) the type of audit opinion that might be rendered by HJ
& Associates, LLC, on the Company's financial statements.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
16.1 Letter of Corbin & Company, LLP dated December 7, 2004 to
the Securities and Exchange Commission.
2
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the Undersigned, thereunto duly authorized.
Sangui Biotech International, INC.
(Registrant)
Date: December 10, 2004 /S/ Wolfgang Barnikol
---------------------------------------
By: Wolfgang Barnikol
Its: President, CEO and CFO
3